BerGenBio to present preliminary data from its BGBC003 clinical trial during oral presentation at ASH 2016

5 Dec 2016 , San Diego, CA

BerGenBio will present translational work from its BGBC003 trial of BGB324 in patients with Acute Myeloid Leukemia.

The oral presentation is entitled:

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Presentation details:
Date: 5 December 2016
Time: 7:00am – 8:30am
Session: 613. Acute Myeloid Leukemia: Clinical Studies: New Drugs for Older AML
Presenter: Prof Dr Dr Sonja Loges
Place: San Diego Ballroom AB (Marriott Marquis San Diego Marina)
Abstract can be viewed here.